Conditions
RSV Infection
Study Overview
This study aims to evaluate the safety and tolerability of clesrovimab compared to palivizumab as assessed by the proportion of participants experiencing adverse events (AEs).
NATIONAL TRIAL REFERENCE NUMBER
NCT04938830
When you talk with your doctor or clinical team member, please have the national trial reference number available.
Resources
Patient Participation
Only a qualified healthcare professional can determine if you are eligible to take part in a clinical trial. However, this information may be useful in starting a conversation with your doctor.
Age Range
0 - 1
Sex
All
Study Details
Trial Phase
Trial Phase 3
In Phase 3 trials, researchers try to find out if a treatment works in a large number of people, usually about 1,000 to 5,000 participants who have the health condition the treatment is intended to treat. In vaccine trials, the participants may be healthy or have diseases or conditions. Phase 3 trials may happen in a doctor’s office, a clinic, or a hospital.
Start Date
End Date
- Actual study start date 11-30-2021
- Estimated primary completion date 04-29-2025
- Estimated study completion date 08-13-2025
Trial Locations
Sorry, there are no locations found.
What can you do next?
If you think this clinical trial might be a good fit and you are interested in taking part, take the next step to see if you are eligible.